We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




German Court Finds in Favor of Puritan in Patent Infringement Case

By LabMedica International staff writers
Posted on 06 Aug 2014
Copan Italia patent infingement claims against Puritan were dismissed by the District Court in Düsseldorf (Germany) at an oral hearing on June 24, 2014, where the court made clear that Puritan’s HydraFlock and PurFlock Ultra flocked swab products are flocked differently and do not have the fiber arrangement claimed by Copan.

Copan Italia SpA (Brecia, Italy; www.copanitalia.com) had started inspection proceedings against Puritan Medical Products Co., LLC (Guilford, MA, USA; www.puritanmedproducts.com) on November 7, 2012, based on an alleged infringement of claim 1 of German utility model DE 20 2004 021 787. More...
Claim 1 relates to flocked swabs and requires that the swabs be covered with fiber deposited by flocking in an ordered arrangement normal to the surface of the swab.

The Court’s findings are particularly relevant since the asserted ‘787 utility model is a branch-off from Copan’s European patent EP 1 608 268 B1 relating to the same invention which also requires fibers deposited by flocking in an ordered arrangement of the fibers normal to the surface of the swab. Thus, it can be concluded from the Court’s clear position regarding the ‘787 that Puritan’s HydraFlock and PurFlock Ultra flocked swabs are also outside the scope of Copan’s European patent.

All of Copan’s German utility models relating to flocked swabs3 expired at the end of March 2014 and are irrelevant for sales from that date forward. Therefore, Puritan and Puritan’s customers have unprejudiced freedom to sell Puritan’s HydraFlock and PurFlock Ultra flocked swabs in Europe without concern for Copan’s European patent or expired utility models.

Puritan Medical Products is an American manufacturer of single-use products for the healthcare, diagnostic, forensic, critical environment, food safety, and drug manufacturing industries.

Related Links:


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.